Stable Coronary Artery Disease Clinical Trial
— DESERTOfficial title:
Des Re-Endothelization for In-StEnt ResTenosis. The DESERT Study
Verified date | July 2013 |
Source | S.M. Misericordia Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Observational |
The hypothesis of this study is that strut coverage occurs earlier when a DES is implanted to treat a BMS restenosis compared with atherosclerotic de-novo lesion. This hypothesis is supported by two different observations: first, when a DES is implanted to treat a BMS restenosis, stent struts are deployed and drugs are eluted on a soft tissue mostly characterized by extracellular matrix with a regular surface. In this case stent malposition is less likely to occur compared to atherosclerotic lesion whose surface is often more irregular and rich in calcium. Second, patients who develop in-stent restenosis after BMS implantation are likely to show a more pronounced neointima hyperplasia and, when a DES is implanted to treat restenosis, reendothelialization is likely to occur earlier. If this hypothesis was verified, duration of dual antiplatelet therapy could be shortened after DES implantation on BMS restenosis with a clinical advantage in terms of bleeding risk. Furthermore, a higher bleeding risk is often a reason for choosing a BMS instead of a DES; thus, patients presenting with BMS restenosis are likely to have a higher bleeding risk and to benefit from a shorter period of dual antiplatelet therapy.
Status | Completed |
Enrollment | 31 |
Est. completion date | July 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: Patients suitable for implantation of everolimus-eluting stents (Xcience V, Xience Prime) because of stable/unstable angina or silent myocardial ischemia due to: - Group A: single BMS restenosis (> 50% of luminal diameter) - Group B: single de-novo lesion (> 50% of luminal diameter) Exclusion Criteria: - contraindications to dual antiplatelet therapy - acute myocardial infarction within the previous 48 hours - significant left main coronary artery disease - reference vessel diameter < 2.5 mm, - hemodynamic instability - chronic kidney disease with serum creatinine > 2 mg/dl - pregnancy - allergy to contrast agent, everolimus, aspirin, clopidogrel - life expectancy < 24 months - patients with possible low adherence to medical therapy |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Italy | Misericordia Hospital | Grosseto |
Lead Sponsor | Collaborator |
---|---|
S.M. Misericordia Hospital |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of uncovered struts evaluated by OCT analysis at six-month follow-up. | Measured will be assessed six-month after coronary angioplasty | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01205425 -
Computed Tomography Coronary Angiography Before Stent Implantation
|
N/A | |
Completed |
NCT03312855 -
Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
|
Phase 2 | |
Completed |
NCT00642811 -
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
|
Phase 2 | |
Recruiting |
NCT03089450 -
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
|
N/A | |
Completed |
NCT01523392 -
A Pharmacodynamic Study With Ticagrelor in African American Patients
|
Phase 4 | |
Completed |
NCT01209637 -
Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD
|
N/A | |
Active, not recruiting |
NCT04434365 -
Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00510588 -
Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease
|
N/A | |
Completed |
NCT03384966 -
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
|
Phase 2 | |
Active, not recruiting |
NCT01609465 -
Prognostic Models for People With Stable Coronary Artery Disease
|
N/A | |
Terminated |
NCT00911339 -
Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents
|
Phase 3 | |
Completed |
NCT00984802 -
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
|
Phase 2 | |
Completed |
NCT03782688 -
Precise Percutaneous Coronary Intervention Plan (P3) Study
|
||
Completed |
NCT02580851 -
Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention
|
N/A | |
Recruiting |
NCT03313752 -
Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
|
Phase 3 | |
Completed |
NCT01184300 -
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
|
Phase 2/Phase 3 | |
Completed |
NCT01523366 -
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
|
Phase 4 | |
Completed |
NCT01118325 -
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
|
Phase 2 | |
Recruiting |
NCT06123728 -
MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease
|